archive-com.com » COM » G » GLSV-VC.COM

Total: 39

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • GLSV - events
    group advised and managed funds totaling more than 200 million With offices in Germany and Switzerland GLSV acted as one team with a global perspective The first fund started its activities in 1996 and invested in 18 companies The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in

    Original URL path: http://www.glsv-vc.com/events/index.html (2016-04-25)
    Open archived version from archive


  • GLSV - Contact
    1996 and invested in 18 companies The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Contact GLSV Industry

    Original URL path: http://www.glsv-vc.com/contact/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Sitemap
    team with a global perspective The first fund started its activities in 1996 and invested in 18 companies The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Team Investment Practice Portfolio FAQ Download Area

    Original URL path: http://www.glsv-vc.com/sitemap.html (2016-04-25)
    Open archived version from archive

  • GLSV - Imprint
    invested in 18 companies The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US After termination of the investment period the fund exited the remaining assets in 2015 and is in liquidation Currenty no new investments are being sought Profile Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Imprint Global Life Science Ventures

    Original URL path: http://www.glsv-vc.com/imprint/index.html (2016-04-25)
    Open archived version from archive

  • GLSV - Latest news & events Archive
    with Leading Cancer Centers MD Anderson Cancer Center and Netherlands Cancer Institute more 23 05 2011 Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS 080 Hepcidin Antagonist Drug Program more 17 05 2011 Zalicus Selected to Join the NASDAQ Biotechnology Index more 11 05 2011 Santaris Pharma A S advances a second drug from its cardiometabolic program SPC4955 inhibiting apoB into Phase 1 clinical trials for the treatment of high cholesterol more 10 05 2011 Agendia Announces Colorectal Cancer Collaboration with AstraZeneca and The Netherlands Cancer Institute more 09 05 2011 Action Pharma completes dosing in phase IIb clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery more 28 04 2011 NeurogesX Receives Notice of Allowance for Patent Covering NGX 1998 Capsaicin Topical Liquid more 25 04 2011 Horizon Pharma Receives FDA Approval of DUEXIS more 18 04 2011 Nabriva Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC 3781 in ABSSSI more 12 04 2011 Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin Therapeutics more 29 03 2011 Zalicus Granted Composition of Matter Patent for Synavive more 21 03 2011 New data published in Nature Genetics demonstrate that tiny LNA based compounds developed by Santaris Pharma A S inhibit entire disease associated microRNA families more 28 02 2011 Santaris Pharma A S obtains exclusive license from Mass General Hospital for intellectual property related to the regulation of miR 33 for the treatment of cardiovascular disorders more 25 02 2011 Zalicus Publishes Data on Sodium Channel Compound in Pain Models more 22 02 2011 Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint Assay more 22 02 2011 Pieris to Present Interim Data from the Phase I Clinical Trial of PRS 050 at Molecular Medicine Tri Conference more 10 01 2011 Zalicus Announces Plans for Advancing Product Candidates more 10 01 2011 Takeda San Francisco and Pieris Sign Anticalin Therapeutic Collaboration more 10 01 2011 Nabriva completes recruitment for Phase II of pleuromutilin antibiotic BC 3781 more 04 01 2011 Pfizer to Pay 14 Million to Use Santaris Technology more 22 12 2010 Intercell starts a Phase I clinical trial for a new vaccine to prevent Clostridium difficile infections more 20 12 2010 Agendia Collaborators Publish Key MammaPrint Paper in Nature Cell Biology more 15 12 2010 Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test ColoPrint more 12 12 2010 Intercell provides update on clinical trials for the patch based Travelers Diarrhea vaccine more 24 11 2010 NeurogesX Appoints New Director to Board more 19 11 2010 NeurogesX Receives Qutenza Specific J Code From Centers for Medicare and Medicaid Services CMS more 11 11 2010 7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS more 08 11 2010 Action Pharma initiates phase IIb clinical trial with AP214 more 02 11 2010 NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX 1998 Liquid Capsaicin Formulation more 19 10 2010 Agendia Establishes Contract with Humana To Cover MammaPrint more 18 10 2010 NeurogesX to Pursue Expanded U S Label for Qutenza R capsaicin 8 Patch in HIV Associated Neuropathy more 28 09 2010 Pieris Signs Broad Collaboration with Sanofi Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics more 22 09 2010 Santaris Pharma A S advances miravirsen the first microRNA targeted drug to enter clinical trials into Phase 2 to treat patients infected with Hepatitis C virus more 15 09 2010 Nabriva Therapeutics Pleuromutilin Antibiotic BC 3781 Shows Therapeutic Potential for Skin and Lung Infections with both Oral and IV Dosing in Non Clinical and Clinical Phase I Studies more 13 09 2010 Action Pharma obtains positive phase II results with AP214 more 09 09 2010 CombinatoRx Changes Company Name to Zalicus Inc more 05 08 2010 Agendia inaugurates new state of the art clinical genomics laboratory in Irvine CA more 03 08 2010 Horizon Pharma Inc Files Registration Statement for Proposed Initial Public Offering more 15 07 2010 Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory Developed Tests more 23 06 2010 Santaris Pharma A S and miRagen Therapeutics Inc form strategic alliance to develop microRNA targeted medicines for the treatment of cardiovascular disease more 15 06 2010 Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound more 12 06 2010 Horizon Pharma Inc Announces Phase 3 Study of LODOTRA Demonstrates 12 Month Sustained Efficacy in Rheumatoid Arthritis more 09 06 2010 Horizon Pharma Announces LODOTRA and HZT 501 Data to be Presented at the European League Against Rheumatism EULAR Annual Congress more 07 06 2010 Pieris AG Appoints Chief Scientific Officer more 07 06 2010 Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214 more 04 06 2010 Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting more 02 06 2010 Nabriva initiates Phase II of pleuromutilin antibiotic BC 3781 more 26 05 2010 7TM Pharma receives milestone payment from asthma and allergy collaboration more 26 05 2010 Horizon Pharma Inc Announces FDA Acceptance of HZT 501 New Drug Application for Filing more 19 05 2010 Horizon Pharma Inc Presents Interim Results from a Pilot Clinical Study Evaluating LODOTRA in the Treatment of Severe Nocturnal Asthma more 30 04 2010 NeurogesX Enters 40 Million Royalty Financing Agreement with Cowen Healthcare Royalty Partners more 30 04 2010 Pieris Announces Positive Preclinical Data on c Met Anticalin Drug Program more 29 04 2010 New Study Demonstrates Patients with High Risk MammaPrint Profile Benefit from Chemotherapy more 26 04 2010 Santaris Pharma A S advances RNA targeted drug development candidate against PCSK9 an important new target for the treatment of high cholesterol more 22 04 2010 A potential new treatment for cancer supportive care and gastrointestinal diseases more 20 04 2010 Agendia and Ferrer inCode Expand MammaPrint Distribution Agreement to Latin America more 01 04 2010 Horizon Therapeutics and Nitec Pharma complete merger and combine businesses more 24 03 2010 Agendia Launches BluePrint Expanding Breast Cancer Product Offering more 17 03 2010 Agendia to Play Pivotal Role in ISPY 2 Trial for Breast Cancer 12 Cancer Drugs Tested 20 Leading U S Cancer Centers Involved more 08 03 2010 Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with small molecule oral once daily AP1030 targeted for type II diabetes associated with obesity more 02 03 2010 FDA Approves Exalgo tm Extended Release Tablets more 09 02 2010 Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists more 04 02 2010 NeurogesX Announces Management Team Promotions more 04 02 2010 7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist more 20 01 2010 7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist more 04 01 2010 Pieris appoints a New CEO more 17 12 2009 Agendia FDA Broadens Clearance for Agendia s MammaPrint more 04 12 2009 New data show breakthrough microRNA targeted therapy developed using Santaris Pharma A S proprietary LNA technology holds promise as new treatment for Hepatitis C more 16 11 2009 NeurogesX Receives FDA Approval of Qutenza capsaicin 8 Patch for Treatment of Postherpetic Neuralgia PHN more 29 10 2009 Nabriva Therapeutics raises Euro 15 Million USD 22 Million more 28 10 2009 Santaris Pharma A S expands executive team appoints Chief Medical Officer and Chief Business Officer to advance proprietary RNA target drug development programs more 20 10 2009 Action Pharma in new phase II clinical trial more 09 10 2009 Pieris reports preclinical progress of its next generation VEGF antagonist more 09 10 2009 Medigene successfully completes patient recruitment into EndoTAG 1 Phase II breast cancer trial more 29 09 2009 MediGene Signs Agreement with Solvay for the Commercialization of Veregen in Germany Austria and Switzerland more 15 09 2009 New collaboration and breakthrough advancements in RNA based drug development programs lead Santaris Pharma A S to establish US operations more 15 09 2009 Pieris AG enters into Anticalin Collaboration with Allergan Inc more 09 09 2009 MediGene AG Receives Marketing Authorization for Veregen in Germany more 02 09 2009 Nitec Pharma reports positive and highly significant Phase III results from CAPRA 2 study of LODOTRA in RA more 24 08 2009 Santaris Pharma A S forms strategic alliance with Shire plc to develop RNA based medicines for the treatment of rare genetic disorders more 10 08 2009 Ikaria to in licence worldwide rights to investigational portfolio from Fibrex Medical more 07 08 2009 MediGene Reports First Six Months of 2009 Revenue Increased Result Improved more 31 07 2009 Cytos CYT003 QbG10 monotherapy for the treatment of allergic rhinoconjunctivitis is safe and efficacious in phase IIb study more 24 07 2009 Santaris Pharma Original paper microRNAs in CNS disorders published in Neuromol Med more 24 07 2009 Neurogesx Announces Preliminary Results of FDA Requested Qutenza Study more 23 07 2009 Nabriva Therapeutics initiates Clinical Phase I trial of pleuromutilin antibiotic BC 3781 more 20 07 2009 Santaris Pharma presents at the World Summit of Antivirals more 17 07 2009 NeurogesX Announces Resignation of Bruce A Peacock from Board of Directors more 14 07 2009 Santaris Pharma Advanced Access publication in Nucleic Acid Research on silencing of miRNA 155 in mice more 09 07 2009 Santaris Pharma publishes interim report for firs half of 2009 more 06 07 2009 Coapt Systems Inc Launches Hydrelle a New FDA Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort more 01 07 2009 CombinatorX and Neuromed Sign Merger Agreement more 29 06 2009 NeurogesX Added to Russell 3000 Index more 24 06 2009 Cytos Biotechnology reports biochemical findings from phase IIa study with hypertension vaccine CYT006 AngQb more 23 06 2009 MediGene Concludes Agreement with Juste for the Commercialization of Veregen in Spain and Portugal more 23 06 2009 Agendia s Breast Cancer Recurrence Test MammaPrint Included in International St Gallen Expert Consensus Recommendations more 22 06 2009 NeurogesX and Astellas Enter Commercialization Agreement for Qutenza more 12 06 2009 CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009 more 11 06 2009 Cytos Biotechnology initiates combined phase I IIa study with a novel anti interleukin 1 beta vaccine in patients with type II diabetes mellitus more 04 06 2009 Santaris LNA based HIF 1 alpha inhibitor shows early signs of clinical benefit more 03 06 2009 Santaris Pharma Director appointed Adjunct Professor in RNA Biology more 03 06 2009 CombinatoRx Announces Positive Results for Aligned Release Synavive more 02 06 2009 NeurogesX Receives FDA Orphan Drug Designation for Qutenza for Treatment of Postherpetic Neuralgia more 27 05 2009 CombinatorX Reports Positive Phase 2 Trial Results for CRx 401 more 26 05 2009 MediGene Presentation of EndoTAG 1 and oHSV Results at the 2009 ASCO Annual more 20 05 2009 FDA Grants Orphan Drug Designation for MediGene s Drug Candidate EndoTAG 1 more 06 05 2009 CombinatorX Announces Oncology Collaboration more 04 05 2009 CombinatoRx Collaborator Fovea Reports Encouraging Clinical Results with CombinatoRx Derived Combination Drug Candidate more 21 04 2009 Cytos Biotechnology initiates phase IIa study with CYT003 QbG10 monotherapy in patients with allergic asthma bronchiale more 07 04 2009 MediGene USPTO Grants Extension of a Patent on Veregen more 24 03 2009 Agendia to Present at BioCentury s Future Leaders in the Biotech Industry Conference more 20 03 2009 Another LNA based RNA Inhibitor Enters Clinical Trials more 19 03 2009 NeurogesX Qutenza NGX 4010 Receives Positive Committee Recommendation in European Union more 05 03 2009 Agendia Appoints Seasoned Diagnostic Executive Albert A Luderer to Supervisory Board more 27 02 2009 NITEC PHARMA COMPLETES RECRUITMENT IN US PHASE III TRIAL FOR LODOTRA more 18 02 2009 Agendia Publishes Direct Evidence that MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer more 12 02 2009 Action Pharma s CEO awarded the Novo Nordisk Prize 2009 more 11 02 2009 Agendia Appoints VP of Business Development more 11 02 2009 Cytos Biotechnology Announces Full Year 2008 Financial Results and Annual Highlights more 10 02 2009 Santaris Pharma A S Enzon announces IND acceptance for its Survivin antagonist more 09 02 2009 Action Pharma recruits Executive Vice President of Business Development to lead the commercialization of the clinical and preclinical drug candidates more 05 02 2009 MediGene to be listed on TecDAX Index more 03 02 2009 Pieris reports development progress for Anticalin PRS 050 a next generation VEGF antagonist more 02 02 2009 Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA based Medicines more 27 01 2009 Intercell was awarded Technology Pioneer by the World Economic Forum in Davos more 16 01 2009 MediGene Presentation of Clinical Data Obtained with EndoTAG 1 for the Treatment of Pancreatic Cancer and with the Oncolytic Virus NV1020 for the Treatment of Metastasized Colorectal Carcinoma at the ASCO GI Meeting more 15 01 2009 7TM Pharma closes a financing round and sells certain early stage discovery assets and technology to OSI Pharmaceuticals more 13 01 2009 Cytos Biotechnology presents analysis of patient diaries including six month follow up data from phase II study with CYT003 QbG10 monotherapy for the treatment of allergic diseases more 12 01 2009 Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA based Medicines more 07 01 2009 Nitec Pharma s new Rheumatoid Arthritis Treatment Lodotra recommended for European Regulatory Approval more 05 01 2009 Pfizer execute s commercial license agreement for novel human vaccines based on Cytos Biotechnology s Immunodrug technology more 22 12 2008 MediGene secures committed standby equity line of up to 25 million Euro more 19 12 2008 NeurogesX Announces FDA Acceptance to Review New Drug Application for NGX 4010 to Treat Post Herpetic Neuralgia more 12 12 2008 Agendia s MammaPrint Predicts to Neoadjuvant Chemotherapy in Breast Cancer more 11 12 2008 Intercell AG wins the Scrip Award for Biotech Company of the year more 09 12 2008 CombinatoRx Presents New Data on B Cell Malignancy Programs more 27 11 2008 MediGene European Patent Office decides to grant new European Patent for Veregen more 22 10 2008 NeurogesX Submits NDA for NGX 4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia PHN more 20 10 2008 MediGene Reports Positive Final Results from EndoTAG TM 1 Phase II Study in Pancreatic Cancer more 17 10 2008 Medigene RhuDex TM to be Examined in Further Laboratory Tests more 15 10 2008 New class of drug candidates developed by Santaris Pharma can potently counteract disease associated microRNAs more 01 10 2008 MediGene Spins Out mTCR Programme Independent Company Immunocore Limited Founded more 29 09 2008 Nitec Pharma AG secures funding of CHF 24M from TVM and Deutsche Bank more 29 09 2008 Medigene Clinical data for EndoTAG TM 1 to be presented at two further medical conferences DVGS UEGW more 21 09 2008 Coapt Sytems Launches FDA Cleared Novielle Voice TM For Restoration Of Voice Loss more 16 09 2008 MediGene reports positive 12 month survival data for EndoTAG TM 1 from Phase II pancreatic cancer study more 15 09 2008 Medigene Appoints Dr Hans Joachim Bochtler as Vice President Clinical Research Development more 09 09 2008 New clinical data for EndoTAG TM 1 to be presented at more 04 09 2008 Agendia Launches TargetPrint for Breast Cancer Patients more 02 09 2008 Fibrex Medical Reports Positive Phase II Results for FX06 more 02 09 2008 7TM Pharma has initiated Phase I IIa clinical trial with TM30339 for the treatment of obesity and related metabolic disorders more 19 08 2008 European Patent Granted on the Application of Anti L1 Antibodies in Cancer Therapy more 31 07 2008 MediGene Sells Licensee Rights to the Drug Oracea to Galderma more 16 07 2008 Wacker validates scalability of Anticalin production with E coli secretion technology and will produce Pieris first clinical candidate PRS 050 more 25 06 2008 Action Pharma presents pre clinical data for treatment of Type 2 diabetes more 24 06 2008 MediGene Achieves Positive Results with RhuDex in Clinical Phase IIa Trial more 24 06 2008 FierceBiotech Names Santaris Pharma as One of the Fierce 15 Biotech Companies of 2008 more 18 06 2008 Santaris Pharma appoints Søren Tulstrup as new President CEO more 16 06 2008 Action Pharma launches a Phase II clinical trial more 12 06 2008 Nitec to present Lodotra 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology EULAR in Paris more 10 06 2008 IMI Intelligent Medical Implants AG announces the appointment of Dr Stephen J McCormack as Chief Executive Officer more 13 05 2008 Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation more 24 04 2008 European Regulatory Authority EMEA Recommends Granting of Marketing Authorization for MediGene s Drug Oracea more 24 04 2008 Intercell was awarded The Vaccine Industry Excellence Award in the category Best New Therapeutic Vaccine for its therapeutic Hepatitis C HCV vaccine candidate more 21 04 2008 Intercell Strong alliance to fight fungal infections more 16 04 2008 7TM Pharma receives milestone payment from asthma and allergy collaboration more 16 04 2008 Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education more 15 04 2008 Intercell s investigational vaccine against Japanese Encephalitis shows excellent safety and immunogenicity in Phase II trials in children more 07 04 2008 MediGene Presents Details of the Excellent Clinical Efficacy Data Obtained with EndoTAG TM 1 in the Indication Pancreatic Carcinoma more 02 04 2008 MediGene Extends Protection for its Innovative EndoTAG TM Technology by Another European Patent more 27 03 2008 Pieris raises 25 M US 38 M in Series B financing round more 12 03 2008 CombinatoRx Drug Candidate CRx 191 Demonstrates

    Original URL path: http://www.glsv-vc.com/news/portfolionews-archive.html (2016-04-25)
    Open archived version from archive

  • GLSV - Investment experience to support growth opportunities
    Focus Key Strengths Track Record Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Investment experience to support growth opportunities successful exits and M A transactions board seat representations Since its foundation in 1996 GLSV has successfully established an attractive portfolio of life science companies The company s first fund GLSV I was invested in 18 ventures The development of this fund was

    Original URL path: http://www.glsv-vc.com/profile/experience.html (2016-04-25)
    Open archived version from archive

  • GLSV - History
    Area News Events Contact Us Home Sitemap Imprint Text size History Founded in 1996 GLSV was one of the first European venture capital firms to focus exclusively on the life science industry The fund was initiated through the support of Dr Stefan Engelhorn the Engelhorn family was the original owner of Boehringer Mannheim HypoVereinsbank Group and ING Barings acted as cosponsors While concentrating on building its track record in the

    Original URL path: http://www.glsv-vc.com/profile/history.html (2016-04-25)
    Open archived version from archive

  • GLSV - Clear focus
    acts as one team with a global perspective Profile Experience History Clear Focus Key Strengths Track Record Team Investment Practice Portfolio FAQ Download Area News Events Contact Us Home Sitemap Imprint Text size Clear focus exclusive focus on the life sciences active early stage investments strong track record From its inception GLSV has benefited from a clear focus by investing exclusively in the life sciences The emphasis is on securing

    Original URL path: http://www.glsv-vc.com/profile/focus.html (2016-04-25)
    Open archived version from archive



  •